In non-small cell lung cancer (NSCLC), reduced expression of RIPK3 and MLKL is significantly associated with poor patient prognosis, suggesting that pathway inactivation may promote tumor immune evasion. The gene discussed is RIPK3; the disease is non-small cell lung carcinoma.